Fibrotic disease is a significant cause of mortality. CCN2 (connective tissue growth factor [CTGF]), a member of the CCN family of matricellular proteins, plays a significant role in driving the fibrogenic effects of cytokines such as transforming growth factor β (TGFβ). It has been proposed that other members of the CCN family can either promote or antagonize the action of CCN2, depending on the context. A recent elegant study published by Bruce Riser and colleagues (Am J Pathol. 174:1725-34, 2009) illustrates that CCN3 (nov) antagonizes the fibrogenic effects of CCN2. This paper, the subject of this commentary, raises the intriguing possibility that CCN3 may be used as a novel anti-fibrotic therapy.
展开▼
机译：纤维化疾病是导致死亡的重要原因。 CCN2（结缔组织生长因子[CTGF]）是母细胞蛋白CCN家族的成员，在驱动细胞因子（例如转化生长因子β（TGFβ））的纤维化作用中起着重要作用。已经提出，取决于上下文，CCN家族的其他成员可以促进或拮抗CCN2的作用。 Bruce Riser及其同事最近发表的一项优雅研究（Am J Pathol。174：1725-34，2009）表明，CCN3（nov）拮抗CCN2的纤维化作用。本文作为本评论的主题，提出了将CCN3用作新型抗纤维化疗法的可能性。
展开▼
